# Huckleberry.ai, Inc.: financial statements, quarterly

HUCK · Nasdaq · CIK 1505952 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/huck.md) · [Financials](/companies/huck/financials.md) · [Filings](/companies/huck/filings.md) · [Insiders](/companies/huck/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/huck/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [79.7](/filings/0001505952-24-000072.md) | [80.2 d](/filings/0001628280-26-025356.md) | [80.1](/filings/0001628280-25-029801.md) | [78.4](/filings/0001505952-25-000075.md) | [79.8](/filings/0001628280-25-055921.md) | [78.8 d](/filings/0001628280-26-025356.md) | [80.1](/filings/0001628280-26-043173.md) | [79.7](/filings/0001628280-26-060537.md) | [79.4](/filings/0001628280-25-055921.md) | [79.6 d](/filings/0001628280-26-025356.md) | [79.4](/filings/0001628280-26-043173.md) | [76.8](/filings/0001628280-26-060537.md) |
| Cost of revenue | $m | [18.8](/filings/0001505952-24-000072.md) | [19.0 d](/filings/0001628280-26-025356.md) | [20.7](/filings/0001628280-25-029801.md) | [20.1](/filings/0001505952-25-000075.md) | [20.0](/filings/0001628280-25-055921.md) | [20.2 d](/filings/0001628280-26-025356.md) | [20.7](/filings/0001628280-26-043173.md) | [20.1](/filings/0001628280-26-060537.md) | [20.5](/filings/0001628280-25-055921.md) | [18.5 d](/filings/0001628280-26-025356.md) | [20.9](/filings/0001628280-26-043173.md) | [17.6](/filings/0001628280-26-060537.md) |
| Gross profit | $m | [60.9](/filings/0001505952-24-000072.md) | [61.1 d](/filings/0001628280-26-025356.md) | [59.4](/filings/0001628280-25-029801.md) | [58.3](/filings/0001505952-25-000075.md) | [59.8](/filings/0001628280-25-055921.md) | [58.6 d](/filings/0001628280-26-025356.md) | [59.4](/filings/0001628280-26-043173.md) | [59.6](/filings/0001628280-26-060537.md) | [58.9](/filings/0001628280-25-055921.md) | [61.1 d](/filings/0001628280-26-025356.md) | [58.5](/filings/0001628280-26-043173.md) | [59.2](/filings/0001628280-26-060537.md) |
| Research and development | $m | [19.7](/filings/0001505952-24-000072.md) | [21.1 d](/filings/0001628280-26-025356.md) | [22.7](/filings/0001628280-25-029801.md) | [22.0](/filings/0001505952-25-000075.md) | [21.3](/filings/0001628280-25-055921.md) | [21.9 d](/filings/0001628280-26-025356.md) | [20.0](/filings/0001628280-26-043173.md) | [19.0](/filings/0001628280-26-060537.md) | [19.1](/filings/0001628280-25-055921.md) | [19.2 d](/filings/0001628280-26-025356.md) | [18.6](/filings/0001628280-26-043173.md) | [17.8](/filings/0001628280-26-060537.md) |
| Operating income | $m | [(11.2)](/filings/0001505952-24-000072.md) | [(13.3) d](/filings/0001628280-26-025356.md) | [(21.5)](/filings/0001628280-25-029801.md) | [(14.5)](/filings/0001505952-25-000075.md) | [(11.1)](/filings/0001628280-25-055921.md) | [(12.3) d](/filings/0001628280-26-025356.md) | [(14.3)](/filings/0001628280-26-043173.md) | [(7.3)](/filings/0001628280-26-060537.md) | [(6.9)](/filings/0001628280-25-055921.md) | [(10.6) d](/filings/0001628280-26-025356.md) | [(11.0)](/filings/0001628280-26-043173.md) | [(2.4)](/filings/0001628280-26-060537.md) |
| Income tax | $m | [0.3](/filings/0001505952-24-000072.md) | [0.5 d](/filings/0001628280-26-025356.md) | [0.1](/filings/0001628280-25-029801.md) | [0.3](/filings/0001505952-25-000075.md) | [0.2](/filings/0001628280-25-055921.md) | [0.6 d](/filings/0001628280-26-025356.md) | [0.2](/filings/0001628280-26-043173.md) | [0.2](/filings/0001628280-26-060537.md) | [0.2](/filings/0001628280-25-055921.md) | [1.1 d](/filings/0001628280-26-025356.md) | [0.4](/filings/0001628280-26-043173.md) | [0.1](/filings/0001628280-26-060537.md) |
| Net income | $m | [(16.4)](/filings/0001505952-24-000072.md) | [(18.7) d](/filings/0001628280-26-025356.md) | [(26.0)](/filings/0001628280-25-055921.md) | [(19.5)](/filings/0001628280-25-055921.md) | [(18.8)](/filings/0001628280-25-055921.md) | [(17.7) d](/filings/0001628280-26-025356.md) | [(18.1)](/filings/0001628280-26-060537.md) | [(22.9)](/filings/0001628280-26-060537.md) | [(10.4)](/filings/0001628280-25-055921.md) | [(8.0) d](/filings/0001628280-26-025356.md) | [(14.2)](/filings/0001628280-26-060537.md) | [(9.6)](/filings/0001628280-26-060537.md) |
| Diluted EPS | $ per share | [(0.45)](/filings/0001505952-24-000072.md) | not reported | [(0.69)](/filings/0001628280-25-029801.md) | [(0.51)](/filings/0001505952-25-000075.md) | [(0.48)](/filings/0001628280-25-055921.md) | not reported | [(0.45)](/filings/0001628280-26-043173.md) | [(0.56)](/filings/0001628280-26-060537.md) | [(0.25)](/filings/0001628280-25-055921.md) | not reported | [(0.33)](/filings/0001628280-26-043173.md) | [(0.21)](/filings/0001628280-26-060537.md) |
| Basic EPS | $ per share | [(0.45)](/filings/0001505952-24-000072.md) | not reported | [(0.69)](/filings/0001628280-25-029801.md) | [(0.51)](/filings/0001505952-25-000075.md) | [(0.48)](/filings/0001628280-25-055921.md) | not reported | [(0.45)](/filings/0001628280-26-043173.md) | [(0.56)](/filings/0001628280-26-060537.md) | [(0.25)](/filings/0001628280-25-055921.md) | not reported | [(0.33)](/filings/0001628280-26-043173.md) | [(0.21)](/filings/0001628280-26-060537.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [60.9](/filings/0001505952-25-000045.md) | [61.2](/filings/0001505952-24-000032.md) | not reported | not reported | [45.3](/filings/0001628280-26-025356.md) | [47.2](/filings/0001628280-25-029801.md) | not reported | not reported | [43.0](/filings/0001628280-26-060537.md) | not reported | [25.1](/filings/0001628280-26-060537.md) |
| Current assets | $m | [136](/filings/0001505952-23-000097.md) | [154](/filings/0001505952-25-000045.md) | [134](/filings/0001505952-24-000032.md) | [129](/filings/0001505952-24-000054.md) | [120](/filings/0001505952-24-000072.md) | [142](/filings/0001628280-26-025356.md) | [117](/filings/0001628280-25-029801.md) | [117](/filings/0001505952-25-000075.md) | [123](/filings/0001628280-25-055921.md) | [154](/filings/0001628280-26-060537.md) | [117](/filings/0001628280-26-043173.md) | [99.7](/filings/0001628280-26-060537.md) |
| Total assets | $m | [208](/filings/0001505952-23-000097.md) | [226](/filings/0001505952-25-000045.md) | [204](/filings/0001505952-24-000032.md) | [198](/filings/0001505952-24-000054.md) | [190](/filings/0001505952-24-000072.md) | [214](/filings/0001628280-26-025356.md) | [190](/filings/0001628280-25-029801.md) | [196](/filings/0001505952-25-000075.md) | [202](/filings/0001628280-25-055921.md) | [236](/filings/0001628280-26-060537.md) | [197](/filings/0001628280-26-043173.md) | [175](/filings/0001628280-26-060537.md) |
| Current liabilities | $m | [217](/filings/0001505952-23-000097.md) | [238](/filings/0001505952-25-000045.md) | [228](/filings/0001505952-24-000032.md) | [225](/filings/0001505952-24-000054.md) | [226](/filings/0001505952-24-000072.md) | [255](/filings/0001628280-26-025356.md) | [231](/filings/0001628280-25-029801.md) | [246](/filings/0001505952-25-000075.md) | [250](/filings/0001628280-25-055921.md) | [271](/filings/0001628280-26-060537.md) | [373](/filings/0001628280-26-043173.md) | [354](/filings/0001628280-26-060537.md) |
| Total liabilities | $m | [359](/filings/0001505952-23-000097.md) | [379](/filings/0001505952-25-000045.md) | [368](/filings/0001505952-24-000032.md) | [364](/filings/0001505952-24-000054.md) | [361](/filings/0001505952-24-000072.md) | [392](/filings/0001628280-26-025356.md) | [368](/filings/0001628280-25-029801.md) | [387](/filings/0001505952-25-000075.md) | [394](/filings/0001628280-25-055921.md) | [422](/filings/0001628280-26-060537.md) | [383](/filings/0001628280-26-043173.md) | [362](/filings/0001628280-26-060537.md) |
| Long-term debt | $m | [112](/filings/0001505952-23-000097.md) | [114](/filings/0001505952-25-000045.md) | [114](/filings/0001505952-24-000032.md) | [115](/filings/0001505952-24-000054.md) | [116](/filings/0001505952-24-000072.md) | [118](/filings/0001628280-26-025356.md) | [120](/filings/0001628280-25-029801.md) | [122](/filings/0001505952-25-000075.md) | [124](/filings/0001628280-25-055921.md) | [126](/filings/0001628280-26-060537.md) | [0.0](/filings/0001628280-26-043173.md) | [0.0](/filings/0001628280-26-060537.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001628280-26-060537.md) | [138](/filings/0001628280-26-060537.md) | [137](/filings/0001628280-26-060537.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [129](/filings/0001628280-26-060537.md) |
| Shareholders' equity | $m | [(151)](/filings/0001505952-24-000072.md) | [(154)](/filings/0001628280-26-025356.md) | [(163)](/filings/0001628280-25-055921.md) | [(166)](/filings/0001628280-25-055921.md) | [(171)](/filings/0001628280-25-055921.md) | [(177)](/filings/0001628280-26-060537.md) | [(179)](/filings/0001628280-26-060537.md) | [(191)](/filings/0001628280-26-060537.md) | [(192)](/filings/0001628280-25-055921.md) | [(186)](/filings/0001628280-26-060537.md) | [(186)](/filings/0001628280-26-060537.md) | [(187)](/filings/0001628280-26-060537.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(4.3) d](/filings/0001505952-24-000072.md) | [5.4 d](/filings/0001628280-26-025356.md) | [1.9](/filings/0001628280-25-029801.md) | [(6.2) d](/filings/0001505952-25-000075.md) | [(13.7) d](/filings/0001628280-25-055921.md) | [8.9 d](/filings/0001628280-26-025356.md) | [4.0](/filings/0001628280-26-043173.md) | [3.4 d](/filings/0001628280-26-060537.md) | [3.4 d](/filings/0001628280-25-055921.md) | [(2.8) d](/filings/0001628280-26-025356.md) | [5.2](/filings/0001628280-26-043173.md) | [(6.4) d](/filings/0001628280-26-060537.md) |
| Capital expenditure | $m | [2.7 d](/filings/0001505952-24-000072.md) | [2.5 d](/filings/0001628280-26-025356.md) | [2.5](/filings/0001628280-25-029801.md) | [2.2 d](/filings/0001505952-25-000075.md) | [2.5 d](/filings/0001628280-25-055921.md) | [2.2 d](/filings/0001628280-26-025356.md) | [2.9](/filings/0001628280-26-043173.md) | [2.3 d](/filings/0001628280-26-060537.md) | [2.3 d](/filings/0001628280-25-055921.md) | [2.4 d](/filings/0001628280-26-025356.md) | [1.8](/filings/0001628280-26-043173.md) | [1.7 d](/filings/0001628280-26-060537.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [34.4](/filings/0001505952-23-000097.md) | [35.2](/filings/0001505952-24-000032.md) | [35.9](/filings/0001505952-24-000054.md) | [36.3](/filings/0001505952-24-000072.md) | [37.5](/filings/0001628280-25-029801.md) | [38.4](/filings/0001505952-25-000075.md) | [38.8](/filings/0001628280-25-055921.md) | [39.7](/filings/0001628280-26-043173.md) | [40.6](/filings/0001628280-26-060537.md) | [41.4](/filings/0001628280-25-055921.md) | [43.4](/filings/0001628280-26-043173.md) | [46.0](/filings/0001628280-26-060537.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.